Scientists Discover Natural Molecules That Could Act As Brakes On Pancreatic Cancer Growth

Natural molecules show potential to curb pancreatic cancer progression

Scientists have identified two naturally occurring microRNAs that may act as a biological brake on the aggressive growth of pancreatic cancer cells. By restoring levels of these molecules, researchers successfully hampered the protein production necessary for tumor expansion, offering a potential new avenue for therapeutic intervention.

The study, published in Physiological Reports, focuses on two specific genetic regulators known as miR-15a and miR-16. These tiny strands of genetic material function by binding to cellular instructions, effectively preventing the synthesis of proteins that cancer cells rely on to divide and proliferate. In the context of pancreatic ductal adenocarcinoma (PDAC), these molecules appear to be deficient, allowing tumors to grow unchecked.

“Cancer cells continually proliferate, or grow and divide,” explains James Fluckey, a professor and principal investigator at the Texas A&M College of Veterinary Medicine and Biomedical Sciences. “To do that, the cells need to increase processes like protein synthesis that give them what they need to grow. If you disrupt that protein synthesis, you can slow the rate at which those cells can grow.”

The research team likened the role of these microRNAs to the braking system of a vehicle. Peter Nghiem, an associate professor at Texas A&M, noted that when these molecules are present, they prevent cells from spiraling into the uncontrolled state associated with malignancy. However, when the team analyzed patient tumor samples, they found that levels of both miR-15a and miR-16 were significantly depleted compared to healthy pancreatic tissue. Intriguingly, lower levels of these molecules were also detected in patients suffering from pancreatitis, an inflammatory condition of the organ.

Beyond identifying the mechanism in laboratory cultures, the researchers examined public clinical data to determine the real-world implications for patients. The findings revealed a compelling correlation: individuals with pancreatic tumors maintaining higher levels of miR-15a and miR-16 experienced improved survival outcomes compared to those with lower expression levels.

Despite these encouraging results, the researchers emphasize that significant hurdles remain before this discovery can be translated into a clinical treatment. The primary challenge lies in precision delivery. Because microRNAs perform essential regulatory tasks throughout the body, any potential therapy must be engineered to restore these molecules specifically within malignant cells while sparing healthy tissue.

“We’re becoming more and more confident that the miR-15a and 16 interventions may truly have therapeutic potential,” Fluckey says. “Now we just have to figure out how to get it to cells in a way that we’re only treating the cells that are cancerous.”

The team does not view this intervention as a standalone cure, given the multifaceted nature of cancer development. Instead, they suggest that these microRNAs could eventually serve as a critical component in a broader, combination treatment regimen designed to disrupt multiple pathways used by tumors to survive and grow. By utilizing tools already present within the human body, the researchers hope to develop more effective, targeted strategies for managing this complex and often devastating disease.